Instil Bio (TIL) Non-Current Debt (2022 - 2026)
Instil Bio (TIL) posted quarterly Non-Current Debt of $85.0 million for Q1 2026, up 0.92% year-over-year from $84.2 million in Q1 2025, and little changed quarter-over-quarter from $84.8 million in Q4 2025.
Instil Bio (TIL) Non-Current Debt (2022 - 2026) Analysis & Trends
Instil Bio's Non-Current Debt history runs 5 years deep, the most recent figure standing at $85.0 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 0.92% year-over-year to $85.0 million; the TTM figure through Mar 2026 stood at $85.0 million (up 0.92% YoY), while the FY2025 annual figure was $84.8 million, up 0.74% from the prior year.
- Non-Current Debt for Q1 2026 stood at $85.0 million, roughly flat from $84.8 million in the prior quarter.
- The five-year high for Non-Current Debt was $85.0 million in Q1 2026, with the low at $49.1 million in Q2 2022.
- The 5-year median for Non-Current Debt is $81.8 million (2024), against an average of $78.7 million.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt surged 65.91% in 2023, then increased 0.5% in 2024.
- Instil Bio's Non-Current Debt stood at $72.4 million in 2022, then increased by 12.55% to $81.4 million in 2023, then rose by 3.39% to $84.2 million in 2024, then climbed by 0.74% to $84.8 million in 2025, then grew by 0.23% to $85.0 million in 2026.
- Business Quant data shows TIL's Non-Current Debt at $85.0 million in Q1 2026, $84.8 million in Q4 2025, and $84.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 8.96 Bn |
| 10 | Instil Bio | 53.44 Mn | 53.44 Mn | - | 85.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.19 Mn |
| Mar 31, 2026 | 85.00 Mn |
| Dec 31, 2025 | 84.81 Mn |
| Sep 30, 2025 | 84.61 Mn |
| Jun 30, 2025 | 84.42 Mn |
| Mar 31, 2025 | 84.23 Mn |
| Dec 31, 2024 | 84.19 Mn |
| Sep 30, 2024 | 82.17 Mn |
| Jun 30, 2024 | 81.93 Mn |
| Mar 31, 2024 | 81.68 Mn |
| Dec 31, 2023 | 81.43 Mn |
| Sep 30, 2023 | 81.18 Mn |
| Jun 30, 2023 | 81.52 Mn |
| Mar 31, 2023 | 77.07 Mn |
| Dec 31, 2022 | 72.35 Mn |
| Sep 30, 2022 | 62.97 Mn |
| Jun 30, 2022 | 49.13 Mn |